Analysts expect that Heat Biologics Inc (NASDAQ:HTBX) will report sales of $910,000.00 for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Heat Biologics’ earnings. The highest sales estimate is $1.10 million and the lowest is $730,000.00. Heat Biologics reported sales of $1.84 million during the same quarter last year, which indicates a negative year-over-year growth rate of 50.5%. The firm is scheduled to announce its next earnings report on Thursday, November 21st.
On average, analysts expect that Heat Biologics will report full year sales of $3.05 million for the current fiscal year, with estimates ranging from $2.89 million to $3.20 million. For the next fiscal year, analysts anticipate that the business will post sales of $2.80 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Heat Biologics.
Heat Biologics (NASDAQ:HTBX) last issued its quarterly earnings data on Wednesday, August 14th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. The company had revenue of $0.34 million during the quarter, compared to analyst estimates of $0.91 million. Heat Biologics had a negative return on equity of 75.51% and a negative net margin of 386.16%.
A hedge fund recently raised its stake in Heat Biologics stock. Vanguard Group Inc. grew its position in shares of Heat Biologics Inc (NASDAQ:HTBX) by 6.8% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,327,660 shares of the biopharmaceutical company’s stock after purchasing an additional 84,400 shares during the period. Vanguard Group Inc. owned approximately 3.90% of Heat Biologics worth $909,000 as of its most recent SEC filing. 5.55% of the stock is currently owned by institutional investors and hedge funds.
Heat Biologics stock traded up $0.01 during mid-day trading on Friday, hitting $0.39. The company’s stock had a trading volume of 89,401 shares, compared to its average volume of 119,371. The firm has a market capitalization of $13.40 million, a PE ratio of -0.44 and a beta of 1.76. Heat Biologics has a 1 year low of $0.35 and a 1 year high of $2.10. The company has a current ratio of 4.50, a quick ratio of 4.50 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average is $0.51 and its two-hundred day moving average is $0.74.
About Heat Biologics
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
See Also: Trading on Margin
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.